Provided by Tiger Trade Technology Pte. Ltd.

Travere Therapeutics, Inc.

52.04
-1.4000-2.62%
Pre-market: 52.990.9500+1.83%07:57 EDT
Volume:1.65M
Turnover:85.89M
Market Cap:4.91B
PE:-109.22
High:53.44
Open:53.44
Low:51.45
Close:53.44
52wk High:68.73
52wk Low:22.59
Shares:94.26M
Float Shares:92.77M
Volume Ratio:0.62
T/O Rate:1.78%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4764
EPS(LYR):-0.2864
ROE:-236.35%
ROA:-3.73%
PB:200.04
PE(LYR):-181.73

Loading ...

Should New FILSPARI Data Require Action From Travere Therapeutics Stock Investors?

Simply Wall St.
·
Oct 07

Travere Therapeutics announces FILSPARI data presentations at ASN Kidney Week

TIPRANKS
·
Oct 02

Travere Says Phase 2 Spartan Final Analysis Shows 75% Complete Proteinuria Remission with Filspari in IgA Nephropathy

Reuters
·
Oct 02

Analysts Offer Insights on Healthcare Companies: Royalty Pharma (RPRX), Travere Therapeutics (TVTX) and Veeva Systems (VEEV)

TIPRANKS
·
Sep 24

Travere Therapeutics Receives US Patent Allowance for Kidney Disease Drug FILSPARI

MT Newswires Live
·
Sep 23

Travere Therapeutics receives notice of allowance for FILSPARI patent

TIPRANKS
·
Sep 23

Travere Therapeutics - Receives USPTO Notice of Allowance for Filspari Patent in FSGS

Reuters
·
Sep 23

Travere Therapeutics, - Receives Uspto Notice of Allowance for Filspari Patent in Fsgs

THOMSON REUTERS
·
Sep 23

Travere Gets USPTO Notice of Allowance for Filspari Use in FSGS Patent Application

Reuters
·
Sep 23

Travere Therapeutics Announces Planned Chief Executive Officer Transition

Reuters
·
Sep 22

Travere Therapeutics CEO Dube to step down

TIPRANKS
·
Sep 22

Travere Therapeutics Names Bradley Campbell CEO, Effective Dec. 1, 2026

Reuters
·
Sep 22

Travere Therapeutics, - Appoints Bradley L. Campbell as President and CEO Effective December 1, 2026

THOMSON REUTERS
·
Sep 22

Travere Therapeutics SVP, Chief Accounting Officer Sandra Calvin Disposes of $335,983 in Common Shares

Reuters
·
Sep 18

Travere Therapeutics Grants Inducement RSUs Covering 56,220 Shares to 16 New Employees

Reuters
·
Sep 12

Travere Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Sep 12

Travere Therapeutics Director Jeffrey A. Meckler Disposes of Common Shares Worth $1.31 Million

Reuters
·
Sep 12

Travere Therapeutics (TVTX) Is Up 6.1% After FILSPARI Beats FSGS Launch Expectations

Simply Wall St.
·
Aug 20

Travere Therapeutics Director Gary A. Lyons Disposes of USD 629,150 in Common Shares

Reuters
·
Aug 20

Travere Therapeutics Posts Corporate Overview on Rare Kidney Disease Growth Strategy, Filspari Expansion and Pipeline Updates

Reuters
·
Aug 14